Clarity Pharmaceuticals Ltd

CU6

AU0000165375

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:11:02 2025-06-19 am EDT			5-day change	1st Jan Change
2.200 ^AUD	+0.92%		-5.98%	-47.24%

Jun. 17	Clarity Pharmaceuticals Enters into a Commercial Manufacturing Agreement with SpectronRx	CI
Jun. 16	Clarity Pharmaceuticals Signs Manufacturing Deal for Diagnostic Product; Shares Rise 5%	MT

Clarity Pharmaceuticals Secures AU$11.1 Million Tax Incentive Refund; Shares Up 12%

Published on 04/17/2025 at 00:25, updated on 04/17/2025 at 00:26

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Enters into a Commercial Manufacturing Agreement with SpectronRx	Jun. 17	CI
Clarity Pharmaceuticals Signs Manufacturing Deal for Diagnostic Product; Shares Rise 5%	Jun. 16	MT
Clarity Pharmaceuticals Enters Commercial Manufacturing Agreement	Jun. 16	RE
Clarity Pharmaceuticals Announces Positive Topline Results from the Diagnostic Phase II SABRE Trial	Jun. 13	CI
Clarity Pharmaceuticals Says Cu-64 SAR-Bombesin Safe, Well Tolerated, Effective In Detecting Prostate Cancer	Jun. 13	RE
Clarity's Trial Shows Radiopharmaceutical Safe, Well Tolerated, Effective in Detecting Prostate Cancer	Jun. 12	MT
Clarity Pharmaceuticals Announces Positive Results from the Diagnostic Phase II DISCO Trial	Jun. 05	CI
Clarity Says Imaging Product Shows Superior Results in Phase 2 Trial Versus Standard of Care; Shares Jump 3%	Jun. 04	MT
Clarity Pharmaceuticals Announces First Patient Imaged in Phase III AMPLIFY Trial with 64Cu-SAR-bisPSMA Pet/CT	May. 29	CI
Clarity Pharmaceuticals Images First Patient in Prostate Cancer Trial	May. 28	MT
Clarity Pharmaceuticals Ltd Announces Registrational Phase III AMPLIFY Trial in Biochemical Recurrence of Prostate Cancer Commences	May. 20	CI
Clarity Begins Phase 3 Trial for Prostate Cancer Imaging Agent	May. 19	MT
Australia shares end at 11-week high on trade relief, rate cut bets	May. 13	RE
Clarity Signs High-Volume Commercial-Scale Copper-64 Supply Agreement With Nusano	Apr. 17	RE
Clarity Pharmaceuticals Signs High-Volume Commercial-Scale Copper-64 Supply Agreement with Nusano	Apr. 17	CI
Clarity Pharmaceuticals Signs Copper Supply Deal With US-Based Physics Firm; Shares Rise 12%	Apr. 17	MT
Clarity Pharmaceuticals Secures AU$11.1 Million Tax Incentive Refund; Shares Up 12%	Apr. 17	MT
Clarity Pharmaceuticals Signs Commercial-Scale Copper-64 Supply Agreement	Apr. 16	RE
Secure Trial Update First Patient Treated In The Phase Ii Cohort Expansion	Apr. 15	RE
Clarity Pharmaceuticals Announces SECuRE Trial Update: First Patient Treated in the Phase II Cohort Expansion	Apr. 15	CI
Clarity Says First Patient Administered Drug Candidate in Prostrate Cancer Trial	Apr. 14	MT
Clarity Pharmaceuticals Announces Completion of the Dose Escalation Phase of the SECuRE Trial	Mar. 05	CI
Clarity Pharmaceuticals Completes Dose Escalation Phase of SECuRE Trial; Shares Rise 4%	Mar. 04	MT
Clarity Pharmaceuticals Signs Copper-64 Isotope Supply Agreement with University of Queensland	Mar. 04	MT
Clarity Pharmaceuticals Fiscal H1 Loss Widens	Feb. 28	MT

Chart Clarity Pharmaceuticals Ltd

Duration

Period

CU6: Dynamic Chart

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.

Employees

Sector

Biotechnology & Medical Research

Calendar

Aug. 19 - Q4 2025 Earnings Release (Projected)

More about the company